During the most recent 90-day period, previous to the date of this filing, there has been one additional insider transaction which has resulted in the acquisition of 8,777 of company shares. This compares with the preceding 90-day window of time where there were 7 transactions from 6 insiders which resulted in the net disposition of 18,704 shares.
This is less than the average level of insider transactions in the 55-company Biopharmaceuticals peer group over the last 90-day period. Within the peer group activity averaged 32.4 transactions per company, with company insiders acquiring on average 102,906 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/899866/000089986619000103/xslF345X03/wf-form4_157550259239392.xml
|Market Chatter: ProSight Global Reportedly in Takeov...|
|Colony Capital's Convertible Senior Notes Offering E...|
|Insider Trends: 90-Days of Insider Buying at World A...|
|Durable Goods Orders Rise for Fourth Straight Month ...|
|Analyst Actions: BofA Securities Adjusts Brookfield ...|